Rybelsus weight loss side effects: what the studies actually show

What did @agata.jedrkowiak actually say?

The video's text and caption do the heavy lifting here. The creator started Rybelsus (oral semaglutide) expecting nausea as the main side effect, then discovered the real surprise: significant body composition changes over several months. Her clothes stopped fitting. Jeans, jackets, and shorts all became too large. The transcript itself is garbled and unusable, so we're working from the caption and hashtags, which tell a clear story about unexpected weight loss on a GLP-1 receptor agonist.

To be direct: the video does not make explicit medical claims. It's a relatable, comedic account of clothes not fitting anymore. But 55,600 viewers watching someone joke about needing a new wardrobe after starting Rybelsus is, functionally, a weight-loss testimonial. That context matters for a fact-check.

Does the science back this up?

Yes, the weight loss experience she describes is well-documented, though the magnitude varies considerably between individuals. Oral semaglutide at therapeutic doses produces meaningful weight reduction, and the timeline of several months aligns with clinical data.

The PIONEER clinical trial program, which tested oral semaglutide across multiple doses, found that participants taking 14mg daily lost an average of 4.4kg over 26 weeks compared to placebo (Aroda et al., 2019, The Lancet). That's meaningful but not dramatic for everyone. The more dramatic results people associate with semaglutide typically come from the subcutaneous injection form (Wegovy), where the STEP 1 trial showed average weight loss of around 14.9% of body weight over 68 weeks (Wilding et al., 2021, New England Journal of Medicine). Oral semaglutide generally delivers less systemic exposure than injections, so individual responses can vary widely. Some people will need new wardrobes. Others won't.

What did they get wrong (or right)?

She got the basic experience right. Nausea is often anticipated as the dominant side effect of semaglutide, and patients frequently underestimate the degree of weight and appetite change. That mismatch between expectation and reality is genuinely common.

What the video skips, understandably for a comedy clip but worth noting here, is that these body changes come with a more complex side-effect profile than just nausea. Gastrointestinal effects including vomiting, constipation, and diarrhea affect a substantial portion of users. The PIONEER 1 trial reported GI adverse events in roughly 40% of participants on oral semaglutide (Rodbard et al., 2019, Diabetes Care). Muscle mass loss alongside fat loss is also a real concern. Research published by Bikou et al. (2024, Nutrients) and others has flagged that GLP-1 agonists can reduce lean mass, which has implications for long-term metabolic health, especially without resistance training. The wardrobe problem is real. The full picture is more complicated.

What should you actually know?

If you're considering Rybelsus or any oral semaglutide product, a few things are worth understanding before you expect the same wardrobe crisis.

• Oral semaglutide has lower bioavailability than injectable semaglutide. It must be taken on an empty stomach with no more than 120ml of water, 30 minutes before food. Getting this wrong significantly reduces absorption (Davies et al., 2017, Diabetes, Obesity and Metabolism).
• Weight loss on GLP-1 agonists is not uniform. Genetics, baseline metabolic health, diet, and activity level all affect outcomes.
• Loss of muscle mass is a documented risk. Without adequate protein intake and resistance training, some of the weight lost may come from lean tissue, not just fat.
• Rybelsus is approved for type 2 diabetes management in most markets, not solely for weight loss. Prescribing context matters, and this medication should only be used under medical supervision.
• If your clothes stop fitting, that's not necessarily a sign everything is going well. Monitoring body composition, not just weight, gives a more accurate picture of health outcomes.

The bottom line

This video is a comedy post, not a health claim, and judging it too harshly would miss the point. But the story it tells, that starting a GLP-1 agonist produces surprisingly dramatic physical changes that nausea warnings don't prepare you for, is accurate as far as it goes. The science supports the experience. What it doesn't tell you is that the full side-effect profile is broader, the degree of weight loss is variable, and the downstream effects on muscle mass deserve attention. Funny content can be accurate and incomplete at the same time.